Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.67 |
| ▸ | PPARG | P37231 | 4/20 | 0.67 |
| ▸ | FBP1 | P09467 | 7/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543477 | 0.88 | PPARA (0.66) | PPARAPPARGFBP1CYP1A2TSHR | |
| SCHEMBL6081371 | 0.86 | PPARA (0.61) | PPARAPPARGFBP1CYP1A2TSHR | |
| SCHEMBL6093013 | 0.86 | PPARA (0.70) | PPARAPPARGFBP1CYP1A2TSHR | |
| SCHEMBL1550516 | 0.85 | PPARA (0.49) | PPARAPPARGFBP1CYP1A2CYP2C19 | |
| SCHEMBL14291406 | 0.85 | PPARA (0.69) | PPARAPPARGFBP1CYP1A2TSHR | |
| SCHEMBL1549446 | 0.85 | PPARA (0.69) | PPARAPPARGFBP1CYP1A2TSHR | |
| SCHEMBL6091395 | 0.85 | PPARA (0.69) | PPARAPPARGFBP1CYP1A2TSHR | |
| SCHEMBL22070757 | 0.85 | PPARA (0.76) | PPARAPPARGFBP1CYP1A2TSHR | |
| SCHEMBL5795203 | 0.84 | PPARG (0.64) | PPARAPPARGCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21188241 | 0.84 | PPARA (0.67) | PPARAPPARGFBP1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | GENFIT (FR) | 2006-04-13 | — | — | US | disclosed |
| EP-1433786-A1 | Benzoxazole compound and pharmaceutical composition containing the compound | Kowa Company Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-6653334-B1 | Electively activate peroxisome proliferator activated receptors | KOWA CO., LTD. (JP) | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | AADAC, NAT1, PARN | PPARA 425/4885PPARG 769/4885FBP1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.